AIP
LCTX icon

Ameritas Investment Partners’s Lineage Cell Therapeutics LCTX Stock Holding History

Ameritas Investment Partners’s Portfolio LCTX Stock Details LCTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-10,656
Closed -$4.81K – 3273
2025
Q1 		$4.81K Hold
10,656
– – ﹤0.01% 2978
2024
Q4 		$5.36K Hold
10,656
– – ﹤0.01% 3017
2024
Q3 		$9.65K Hold
10,656
– – ﹤0.01% 2934
2024
Q2 		$10.6K Hold
10,656
– – ﹤0.01% 2900
2024
Q1 		$15.8K Hold
10,656
– – ﹤0.01% 2664
2023
Q4 		$11.6K Hold
10,656
– – ﹤0.01% 2799
2023
Q3 		$12.6K Hold
10,656
– – ﹤0.01% 2730
2023
Q2 		$15K Buy
+10,656
New +$14.7K ﹤0.01% 2713
2022
Q2 		– Sell
-9,508
Closed -$15K – 3159
2022
Q1 		$15K Hold
9,508
– – ﹤0.01% 2668
2021
Q4 		$23K Hold
9,508
– – ﹤0.01% 2576
2021
Q3 		$24K Hold
9,508
– – ﹤0.01% 2601
2021
Q2 		$27K Buy
+9,508
New +$24.6K ﹤0.01% 2568
2020
Q2 		– Sell
-6,005
Closed -$5K – 3100
2020
Q1 		$5K Hold
6,005
– – ﹤0.01% 2814
2019
Q4 		$5K Hold
6,005
– – ﹤0.01% 2901
2019
Q3 		$6K Hold
6,005
– – ﹤0.01% 2894
2019
Q2 		$7K Hold
6,005
– – ﹤0.01% 2886
2019
Q1 		$8K Hold
6,005
– – ﹤0.01% 2764
2018
Q4 		$5K Sell
6,005
-859
-13% -$1.32K ﹤0.01% 2858
2018
Q3 		$14K Hold
6,864
– – ﹤0.01% 2692
2018
Q2 		$12K Hold
6,864
– – ﹤0.01% 2780
2018
Q1 		$16K Hold
6,864
– – ﹤0.01% 2526
2017
Q4 		$13K Hold
6,864
– – ﹤0.01% 2658
2017
Q3 		$17K Hold
6,864
– – ﹤0.01% 2518
2017
Q2 		$19K Hold
6,864
– – ﹤0.01% 2487
2017
Q1 		$21K Buy
+6,864
New +$19.5K ﹤0.01% 2375

Other funds holding LCTX

BC
Broadwood Capital New York $1.42B AUM 34.72% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
DC
Defender Capital Charlotte, North Carolina $308M AUM 4.52% 1-Year Est. Return
RA
Raffles Associates New York $115M AUM 35.69% 1-Year Est. Return
Comerica Bank
Comerica Bank Dallas, Texas $25.1B AUM 24.68% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Jane Street
Jane Street New York $777B AUM 61.18% 1-Year Est. Return

Ameritas Investment Partners's LCTX Position: Q2 2025 in Review

Ameritas Investment Partners sold out of Lineage Cell Therapeutics (LCTX) in Q2 2025, closing a stake of 10,656 shares — an estimated $4.81K sold.

Ameritas Investment Partners first reported a position in LCTX in Q1 2017 and held it in 25 quarters. The position peaked at $27K in Q2 2021. 129 funds tracked by Wall St. Rank hold LCTX as of Q2 2025.

  • Ameritas Investment Partners reported no remaining Lineage Cell Therapeutics position as of Q2 2025 after selling out during the quarter.
  • Ameritas Investment Partners sold 10,656 Lineage Cell Therapeutics shares in Q2 2025, an estimated $4.81K.
  • Ameritas Investment Partners first reported a position in Lineage Cell Therapeutics in Q1 2017 and held it in 25 quarters.
  • Ameritas Investment Partners's Lineage Cell Therapeutics position peaked at $27K in Q2 2021.
  • 129 funds tracked by Wall St. Rank held Lineage Cell Therapeutics as of Q2 2025.

Based on Ameritas Investment Partners's 13F filing for Q2 2025, filed 12 Aug 2025.